Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

One of the major goals of cancer immunotherapy is the induction of tumour-specific T-lymphocyte responses that will be effective in the rejection of established tumours. The prospects for such therapy rely on the identification of tumour antigens, and although there is persuasive evidence for the presence of such antigens,1,2 the occurrence of the disease does illustrate that the immune system is at least, on some occasions, unable to recognise and destroy these targets. Tumour antigens may be novel proteins (from genetic lesions or viral infections), modified existing antigens (eg, abnormally glycosylated cell surface proteins), or inappropriately expressed normal gene products (eg, CA125, carcinoembryonic antigen, and alpha-fetoprotein).1 Involvement of the immune system in the normal surveillance and suppression of cancer is further suggested by the increased incidence of tumours in immunocompromised patients.3 However, recent evidence has shown that, at least in model systems, cancer cells can be modulated in such a way that they stimulate cells of the immune system to recognise and destroy these malignant cells. This review summarizes the costimulatory molecules involved in the activation of such cells, the principles and mechanisms underlying their activation, and how such knowledge can be used to persuade the immune system to challenge cancer.

Type

Journal article

Journal

Cancer gene therapy

Publication Date

05/1996

Volume

3

Pages

202 - 214

Addresses

Department of Molecular Medicine, King's College School of Medicine and Dentistry, Rayne Institute, London, England.

Keywords

Killer Cells, Natural, T-Lymphocytes, Animals, Humans, Neoplasms, Receptors, Antigen, T-Cell, Antigens, CD28, Antigens, Differentiation, Antigens, CD, Antigens, CD80, Tumor Markers, Biological, Immunoconjugates, Antigens, Neoplasm, Antigens, Surface, Immunotherapy, Signal Transduction, Cytotoxicity, Immunologic, Immunocompromised Host, Models, Immunological, CTLA-4 Antigen, Genetic Therapy